Staidson Beijing BioPharmaceuticals Co., Ltd. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced sales was CNY 115.456 million compared to CNY 54.881 million a year ago. Operating loss was CNY 19.868 million compared to CNY 24.582 million a year ago. Net loss was CNY 19.908 million compared to CNY 24.737 million a year ago. Basic loss per share from continuing operations was CNY 0.04 compared to CNY 0.05 a year ago.